118 related articles for article (PubMed ID: 1500026)
21. The prognostic implications of low serum CA 125 levels prior to the second-look operation for stage III and IV epithelial ovarian cancer.
Gallion HH; Hunter JE; van Nagell JR; Averette HE; Cain JM; Copeland LJ; Higgins RV; Husseinzadeh N; Nahhas WA; Partridge EE
Gynecol Oncol; 1992 Jul; 46(1):29-32. PubMed ID: 1634137
[TBL] [Abstract][Full Text] [Related]
22. Ovarian tumors of low malignant potential (borderline tumors): immune morphology and current status.
Neunteufel W; Gitsch G; Schieder K; Kölbl H; Breitenecker G
Anticancer Res; 1989; 9(4):993-7. PubMed ID: 2684001
[TBL] [Abstract][Full Text] [Related]
23. Recurrence and prognostic factors in borderline ovarian tumors.
Ayhan A; Guvendag Guven ES; Guven S; Kucukali T
Gynecol Oncol; 2005 Sep; 98(3):439-45. PubMed ID: 16009407
[TBL] [Abstract][Full Text] [Related]
24. Preoperative serum CA-125 levels in early stage ovarian cancer.
Patsner B
Eur J Gynaecol Oncol; 1990; 11(5):319-21. PubMed ID: 2097148
[TBL] [Abstract][Full Text] [Related]
25. Epithelial ovarian tumors of borderline malignancy.
Chao TM; Yen MS; Chao KC; Ng HT
Zhonghua Yi Xue Za Zhi (Taipei); 1996 Aug; 58(2):97-102. PubMed ID: 8915111
[TBL] [Abstract][Full Text] [Related]
26. Ovarian epithelial tumors of borderline malignancy in Japan.
Nakashima N; Nagasaka T; Oiwa N; Nara Y; Fukata S; Fukatsu T; Takeuchi J
Gynecol Oncol; 1990 Jul; 38(1):90-8. PubMed ID: 2162318
[TBL] [Abstract][Full Text] [Related]
27. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
Ayhan A; Guven S; Guven ES; Kucukali T
Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
[TBL] [Abstract][Full Text] [Related]
28. Ovarian serous borderline tumors with micropapillary and cribriform patterns: a study of 40 cases and comparison with 44 cases without these patterns.
Eichhorn JH; Bell DA; Young RH; Scully RE
Am J Surg Pathol; 1999 Apr; 23(4):397-409. PubMed ID: 10199469
[TBL] [Abstract][Full Text] [Related]
29. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal.
van Haaften-Day C; Shen Y; Xu F; Yu Y; Berchuck A; Havrilesky LJ; de Bruijn HW; van der Zee AG; Bast RC; Hacker NF
Cancer; 2001 Dec; 92(11):2837-44. PubMed ID: 11753957
[TBL] [Abstract][Full Text] [Related]
30. Mucinous tumors of the ovary: a clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas.
Rodríguez IM; Prat J
Am J Surg Pathol; 2002 Feb; 26(2):139-52. PubMed ID: 11812936
[TBL] [Abstract][Full Text] [Related]
31. Preoperative measurement of cancer antigen 125 (CA 125) in the differential diagnosis of ovarian tumors.
Mogensen O; Mogensen B; Jakobsen A; Sell A
Acta Oncol; 1989; 28(4):471-3. PubMed ID: 2789822
[TBL] [Abstract][Full Text] [Related]
32. [Clinical significance of the tumor marker CA-125 for the preoperative diagnosis and postoperative management of patients with malignant ovarian cancers].
Sevelda P; Salzer H; Dittrich C; Spona J
Geburtshilfe Frauenheilkd; 1985 Nov; 45(11):769-73. PubMed ID: 3865860
[TBL] [Abstract][Full Text] [Related]
33. Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor.
Tamakoshi K; Kikkawa F; Shibata K; Tomoda K; Obata NH; Wakahara F; Tokuhashi Y; Ishikawa H; Kawai M; Tomoda Y
Gynecol Oncol; 1996 Jul; 62(1):67-72. PubMed ID: 8690294
[TBL] [Abstract][Full Text] [Related]
34. Genetic alterations of serous borderline tumors of the ovary compared to stage I serous ovarian carcinomas.
Osterberg L; Akeson M; Levan K; Partheen K; Zetterqvist BM; Brännström M; Horvath G
Cancer Genet Cytogenet; 2006 Jun; 167(2):103-8. PubMed ID: 16737908
[TBL] [Abstract][Full Text] [Related]
35. Ultrasound, physical examination, and CA 125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumors.
Zanetta G; Rota S; Lissoni A; Meni A; Brancatelli G; Buda A
Gynecol Oncol; 2001 Apr; 81(1):63-6. PubMed ID: 11277651
[TBL] [Abstract][Full Text] [Related]
36. The impact of clinicopathologic and surgical factors on relapse and pregnancy in young patients (≤40 years old) with borderline ovarian tumors.
Fang C; Zhao L; Chen X; Yu A; Xia L; Zhang P
BMC Cancer; 2018 Nov; 18(1):1147. PubMed ID: 30463533
[TBL] [Abstract][Full Text] [Related]
37. Borderline Ovarian Tumors: Fifteen Years' Experience at a Scottish Tertiary Cancer Center.
May J; Skorupskaite K; Congiu M; Ghaoui N; Walker GA; Fegan S; Martin CW; O'Donnell RL
Int J Gynecol Cancer; 2018 Nov; 28(9):1683-1691. PubMed ID: 30365457
[TBL] [Abstract][Full Text] [Related]
38. Autoimplants in serous borderline tumors of the ovary: a clinicopathologic study of 30 cases of a process to be distinguished from serous adenocarcinoma.
Rollins SE; Young RH; Bell DA
Am J Surg Pathol; 2006 Apr; 30(4):457-62. PubMed ID: 16625091
[TBL] [Abstract][Full Text] [Related]
39. Restaging surgery for women with borderline ovarian tumors: results of a French multicenter study.
Fauvet R; Boccara J; Dufournet C; David-Montefiore E; Poncelet C; Daraï E
Cancer; 2004 Mar; 100(6):1145-51. PubMed ID: 15022280
[TBL] [Abstract][Full Text] [Related]
40. [Monoclonal antibodies in the diagnosis and follow-up of ovarian cancer. CA 125 as a tumor marker. A cooperative study of the Gynecologic Tumor Marker Group (GTMG)].
Kaesemann H; Caffier H; Hoffmann FJ; Crombach G; Würz H; Kreienberg R; Möbus V; Schmidt-Rhode P; Sturm G
Klin Wochenschr; 1986 Sep; 64(17):781-5. PubMed ID: 3463828
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
